Coke said in September that it was “closely watching” the growth of CBD as a possible ingredient for so-called wellness beverages. At the same time rumors swirled that Coke was considering an investment in Canadian cannabis company Aurora (ACB).

Even though Coke shot down chatter of an imminent deal with Aurora or other cannabis companies, there is still growing interest in CBD from larger global consumer companies ever since recreational marijuana became legal in Canada earlier this month.

Coke’s archrival Pepsi (PEP) hasn’t completely ruled out a move into cannabis. Chief Financial Officer Hugh Johnston told analysts during its earnings call earlier this month that “it’s fair to say we look at everything” in response to a question about cannabis.

But Johnston added that investing in CBD, especially in the United States, would be a “considerable challenge” as long as marijuana remains illegal on a federal level. It’s legal in nine states and D.C.

That murky legal status hasn’t kept the beer and spirits makers at bay.

Corona owner Constellation Brands (STZ) has a more than $4 billion stake in Canopy Growth.

The Canadian subsidiary of Molson Coors (TAP) has a joint venture with The Hydropothecary Corporation to produce cannabis-infused drinks for the Canadian market.

Tobacco giant Altria (MO), the owner of Marlboro, may be mulling a stake in Aphria, which is also set to debut on the NYSE later this week. UK alcoholic beverage giant Diageo (DEO) also could be interested in cannabis.